Exploring the underlying mechanisms of drug‐induced impulse control disorders: a pharmacovigilance‐pharmacodynamic study

Impulse control disorders (e.g. pathological gambling, hypersexuality) may develop as adverse reactions to drugs. Pathogenetic hypotheses have mainly focused on D3‐receptor agonism, and switching to alternatives with different pharmacologic mechanisms represents a common management strategy. Nonetheless, treatment failure is common and gaining pathophysiological insights is needed.

[1]  G. Trifirò,et al.  Post-Marketing Surveillance of CAR-T-Cell Therapies: Analysis of the FDA Adverse Event Reporting System (FAERS) Database , 2022, Drug Safety.

[2]  M. Menchetti,et al.  Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System , 2022, The international journal of neuropsychopharmacology.

[3]  E. Poluzzi,et al.  Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System , 2022, Drug Safety.

[4]  I. Wilting,et al.  Impulse control disorders associated with dopaminergic drugs: A disproportionality analysis using vigibase , 2022, European Neuropsychopharmacology.

[5]  A. Lees,et al.  Reply to 'Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study.' , 2021, Parkinsonism & related disorders.

[6]  Ç. Ermiş,et al.  Selective serotonin reuptake inhibitors and manic switch: A pharmacovigilance and pharmacodynamical study. , 2021, Asian journal of psychiatry.

[7]  T. Jhou.  The rostromedial tegmental (RMTg) “brake” on dopamine and behavior: A decade of progress but also much unfinished work , 2021, Neuropharmacology.

[8]  M. Menchetti,et al.  Impulsive conditions in Parkinson's disease: A pharmacosurveillance-supported list. , 2021, Parkinsonism & related disorders.

[9]  D. Brooks,et al.  Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study. , 2021, Parkinsonism & related disorders.

[10]  A. Håkansson,et al.  Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden , 2021, PloS one.

[11]  T. Morera-Herreras,et al.  Do cariprazine and brexpiprazole cause impulse control symptoms? A case/non-case study , 2021, European Neuropsychopharmacology.

[12]  N. Sousa,et al.  Assessing Impulsivity in Humans and Rodents: Taking the Translational Road , 2021, Frontiers in Behavioral Neuroscience.

[13]  B. Elfving,et al.  Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task , 2021, Scientific Reports.

[14]  C. Winstanley,et al.  Impulse Control Disorders in Parkinson’s Disease: From Bench to Bedside , 2021, Frontiers in Neuroscience.

[15]  E. Clementi,et al.  Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review , 2021, The international journal of neuropsychopharmacology.

[16]  C. Winstanley,et al.  Pharmacological evidence of a cholinergic contribution to elevated impulsivity and risky decision-making caused by adding win-paired cues to a rat gambling task , 2021, Journal of psychopharmacology.

[17]  K. Kaneda,et al.  Role of 5-HT1A receptor-mediated serotonergic transmission in the medial prefrontal cortex in acute restraint stress-induced augmentation of rewarding memory of cocaine in mice , 2020, Neuroscience Letters.

[18]  S. Leucht,et al.  Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. , 2020, Schizophrenia bulletin.

[19]  Minmin Luo,et al.  Reward Contributions to Serotonergic Functions. , 2020, Annual review of neuroscience.

[20]  C. Missale,et al.  Dopamine D3 Receptor Heteromerization: Implications for Neuroplasticity and Neuroprotection , 2020, Biomolecules.

[21]  J. Montastruc,et al.  Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study , 2020, European Journal of Clinical Pharmacology.

[22]  L. Wilkinson,et al.  Effects of 5-HT2C, 5-HT1A receptor challenges and modafinil on the initiation and persistence of gambling behaviours , 2020, Psychopharmacology.

[23]  J. Engelmann,et al.  A neuroeconomic investigation of 5-HTT/5-HT1A gene variation, social anxiety, and risk-taking behavior , 2020, Anxiety, stress, and coping.

[24]  S. Steidl,et al.  Rewarding effects of M4 but not M3 muscarinic cholinergic receptor antagonism in the rostromedial tegmental nucleus , 2019, Behavioural Brain Research.

[25]  E. Clementi,et al.  Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase® , 2019, Expert opinion on drug safety.

[26]  D. Weintraub.  Impulse control disorders in Parkinson's disease: A 20‐year odyssey , 2019, Movement disorders : official journal of the Movement Disorder Society.

[27]  M. Lapeyre-Mestre,et al.  Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. , 2019, Therapie.

[28]  Andrew R. Leach,et al.  ChEMBL: towards direct deposition of bioassay data , 2018, Nucleic Acids Res..

[29]  E. Clementi,et al.  Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance–Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database , 2019, CNS Drugs.

[30]  Stefano Tamburin,et al.  Dopaminergic Neurotransmission in Patients With Parkinson's Disease and Impulse Control Disorders: A Systematic Review and Meta-Analysis of PET and SPECT Studies , 2018, Front. Neurol..

[31]  P. Fletcher,et al.  Dorsal raphe serotonin neurons inhibit operant responding for reward via inputs to the ventral tegmental area but not the nucleus accumbens: evidence from studies combining optogenetic stimulation and serotonin reuptake inhibition , 2018, Neuropsychopharmacology.

[32]  P. Jolliet,et al.  Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase , 2018, British journal of clinical pharmacology.

[33]  G. Papazisis,et al.  Detecting a potential safety signal of antidepressants and type 2 diabetes: a pharmacovigilance‐pharmacodynamic study , 2018, British journal of clinical pharmacology.

[34]  J. Montastruc,et al.  Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus: A Pharmacoepidemiological–Pharmacodynamic Study in VigiBase® , 2018, Drug Safety.

[35]  M. Vidailhet,et al.  Longitudinal analysis of impulse control disorders in Parkinson disease , 2018, Neurology.

[36]  J. Wess,et al.  Muscarinic M4 Receptors on Cholinergic and Dopamine D1 Receptor-Expressing Neurons Have Opposing Functionality for Positive Reinforcement and Influence Impulsivity , 2018, Front. Mol. Neurosci..

[37]  O. Tysnes,et al.  Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson’s Disease , 2018, Front. Neurol..

[38]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[39]  K Domschke,et al.  Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 , 2017, Pharmacopsychiatry.

[40]  P. Derkinderen,et al.  Dopamine Agonists and Impulse Control Disorders: A Complex Association , 2017, Drug Safety.

[41]  M. Lapeyre-Mestre,et al.  Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics , 2017, British journal of clinical pharmacology.

[42]  D. Weintraub,et al.  Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy , 2017, Seminars in Neurology.

[43]  H. Fernandez,et al.  Dopamine agonist withdrawal syndrome: A comprehensive review , 2017, Journal of the Neurological Sciences.

[44]  O. Rascol,et al.  An original pharmacoepidemiological–pharmacodynamic method: application to antipsychotic‐induced movement disorders , 2017, British journal of clinical pharmacology.

[45]  N. Sousa,et al.  Reappraising striatal D1- and D2-neurons in reward and aversion , 2016, Neuroscience & Biobehavioral Reviews.

[46]  N. Costes,et al.  Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study , 2016, Scientific Reports.

[47]  M. Lapeyre-Mestre,et al.  Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase , 2015, European Neuropsychopharmacology.

[48]  Robert M Sears,et al.  Serotonin (5-HT) 5-HT2A Receptor (5-HT2AR):5-HT2CR Imbalance in Medial Prefrontal Cortex Associates with Motor Impulsivity. , 2015, ACS chemical neuroscience.

[49]  P. Seeman.  Parkinson's disease treatment may cause impulse–control disorder via dopamine D3 receptors , 2015, Synapse.

[50]  J. Kauer,et al.  Stress and VTA synapses: implications for addiction and depression , 2014, The European journal of neuroscience.

[51]  C. Tung,et al.  Acute and subchronic effects of buspirone on attention and impulsivity in the five-choice serial reaction time task in rats , 2013, Neuroscience Letters.

[52]  Yu Ohmura,et al.  Tandospirone suppresses impulsive action by possible blockade of the 5-HT1A receptor. , 2013, Journal of pharmacological sciences.

[53]  C. Gremel,et al.  Strengthening the accumbal indirect pathway promotes resilience to compulsive cocaine use , 2013, Nature Neuroscience.

[54]  Marios Politis,et al.  Neural response to visual sexual cues in dopamine treatment-linked hypersexuality in Parkinson's disease. , 2013, Brain : a journal of neurology.

[55]  Johan Hopstadius,et al.  Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery , 2011, Statistical methods in medical research.

[56]  Maria F. Sassano,et al.  Automated design of ligands to polypharmacological profiles , 2012, Nature.

[57]  E. Hollander,et al.  Impulse-control disorders not elsewhere classified. , 2012 .

[58]  J. Tsien,et al.  NMDA Receptors in Dopaminergic Neurons Are Crucial for Habit Learning , 2011, Neuron.

[59]  A. Greenshaw,et al.  5-HT receptors and reward-related behaviour: A review , 2011, Neuroscience & Biobehavioral Reviews.

[60]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[61]  K. Doya,et al.  Activation of the central serotonergic system in response to delayed but not omitted rewards , 2011, The European journal of neuroscience.

[62]  Rune W. Berg,et al.  Influence of Phasic and Tonic Dopamine Release on Receptor Activation , 2010, The Journal of Neuroscience.

[63]  G. Kranz,et al.  Reward and the serotonergic system , 2010, Neuroscience.

[64]  G. Juhász,et al.  Significant association between the C(−1019)G functional polymorphism of the HTR1A gene and impulsivity , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[65]  Ben M. Crittenden,et al.  Dissociable Control of Impulsivity in Rats by Dopamine D2/3 Receptors in the Core and Shell Subregions of the Nucleus Accumbens , 2010, Neuropsychopharmacology.

[66]  K. Deisseroth,et al.  Phasic Firing in Dopaminergic Neurons Is Sufficient for Behavioral Conditioning , 2009, Science.

[67]  Ming D. Li,et al.  Significant association of DRD1 with nicotine dependence , 2008, Human Genetics.

[68]  V. Voon,et al.  Medication-related impulse control and repetitive behaviors in Parkinson disease. , 2007, Archives of neurology.

[69]  Young T. Hong,et al.  Nucleus Accumbens D2/3 Receptors Predict Trait Impulsivity and Cocaine Reinforcement , 2007, Science.

[70]  A. Hoes,et al.  Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. , 2005, European heart journal.

[71]  Y. P. Liu,et al.  Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex , 2004, Psychopharmacology.

[72]  J. Joyce,et al.  Distribution of Dopamine D3 Receptor Expressing Neurons in the Human Forebrain: Comparison with D2 Receptor Expressing Neurons , 1999, Neuropsychopharmacology.

[73]  D. Comings,et al.  Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors , 1997, Molecular Psychiatry.